Effects of Stem Cell Treatment in Human Patients With Peyronie Disease Jason A. Levy, OMS III, MS; Melissa Marchand, PA-C; Leanne Iorio, OMS I; Gilles Zribi; Michael P. Zahalsky, MD Author Notes The Journal of the American Osteopathic Association,
October 2015, Vol. 115, e8-e13. doi:10.7556/jaoa.2015.124
Abstract
Context: Peyronie disease (PD) is a connective tissue disorder involving the formation of fibrous plaques in the tunica albuginea. Abnormal plaques and scar tissue create a chronic state of inflammation, causing increased curvature of the penis as well as erectile dysfunction.
Objective: To determine the feasibility and effects of using placental matrix–derived mesenchymal stem cells (PM-MSCs) in the management of PD.
Methods: In a prospective study, patients with PD were injected with PM-MSCs, and followed up at 6-week, 3-month, and 6-month intervals to assess changes in plaque volume, penile curvature, and erectile function status (measured using peak systolic velocity, end-diastolic velocity, and the International Index of Erectile Function questionnaire).
Results: In the 5 patients enrolled in the study, statistically significant increases in peak systolic velocity occurred after PM-MSC injection (P<.01). Of a total of 10 plaques managed, 7 had disappeared completely at 3-month follow-up. Changes in end-diastolic velocity, stretched penile length, and penile girth were not statistically significant.
Conclusion: To our knowledge, this study is the first on the use of stem cells to manage PD in humans. The results suggest that PM-MSCs may be beneficial and effective as a nonsurgical treatment in patients with PD. Future studies with long-term follow-up in a larger sample of patients are warranted. (ClinicalTrials.gov number NCT02395029)
